Decrease in revenue but increase in profits! Contemporary Amperex Technology will generate over 50 billion in 2024｜Interpretations
① In 2024, Contemporary Amperex Technology's performance will see a decrease in revenue but an increase in profit, with a Net income reaching 50.7 billion yuan; ② The Battery Business remains the largest source of revenue for Contemporary Amperex Technology; ③ The inventory impairment reserve of Contemporary Amperex Technology has significantly increased compared to the previous year.
The "King Ning" is heading towards a new battlefield.
Reconstruct the Global Industry Chain.
Track Hyper | Zhejiang Sanhua Intelligent Controls: Tesla "T-chain" Bright Card.
Similar to Ningbo Tuopu Group, but there are risks.
Is Imeik Technology Development's premium of 13 times for controlling the leading aesthetic medical brand in South Korea too high?| K Commentary
① Imeik Technology Development holds a 13 times premium stake in South Korea's REGEN Biotech, which possesses two core products, AestheFill and PowerFill; ② If Imeik Technology Development wants to reclaim exclusive agency rights for AestheFill in China from JiangSu WuZhong Pharmaceutical Development, certain costs will inevitably need to be incurred; ③ The competition in the medical beauty regeneration sector is intensifying, and recently two hydroxyapatite products have been approved.
Is Baijiu(Chinese Liquor) saved? After the Spring Festival, several Baijiu(Chinese Liquor) Funds rose over 10%. Have the investors who entered at a high point recovered their capital?
① Funds heavily invested in Baijiu are rebounding, with many products increasing over 10% after the holiday; ② Investors who poured into funds focused on Baijiu three years ago are still at a loss; ③ A total of 19 related Baijiu stocks are heavily held by public funds, with the market value of Kweichow Moutai's heavy holdings significantly reduced from its peak.
Another one! The "A+H" wave continues as Lens Technology plans to list in Hong Kong | Quick announcement
① Lens Technology plans to issue H shares and be listed on the Main Board of the Hong Kong Stock Exchange. ② This year, several listed companies are planning the "A+H" listing model in order to accelerate the promotion of their Global Strategy.